|
Sep 20
|
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
|
|
Aug 8
|
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript
|
|
Aug 8
|
Q3 2023 Arrowhead Pharmaceuticals Inc Earnings Call
|
|
May 25
|
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
|
|
May 22
|
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now
|